ATE374030T1 - Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten - Google Patents
Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheitenInfo
- Publication number
- ATE374030T1 ATE374030T1 AT04741126T AT04741126T ATE374030T1 AT E374030 T1 ATE374030 T1 AT E374030T1 AT 04741126 T AT04741126 T AT 04741126T AT 04741126 T AT04741126 T AT 04741126T AT E374030 T1 ATE374030 T1 AT E374030T1
- Authority
- AT
- Austria
- Prior art keywords
- acute
- treatment
- combination
- neurological diseases
- chronic neurological
- Prior art date
Links
- 229940124596 AChE inhibitor Drugs 0.000 title 1
- 101150016175 Grm2 gene Proteins 0.000 title 1
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 title 1
- 230000001154 acute effect Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000001684 chronic effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03016968 | 2003-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE374030T1 true ATE374030T1 (de) | 2007-10-15 |
Family
ID=34130033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04741126T ATE374030T1 (de) | 2003-07-25 | 2004-07-17 | Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7235547B2 (de) |
| EP (1) | EP1651234B1 (de) |
| JP (1) | JP5005343B2 (de) |
| KR (1) | KR100764330B1 (de) |
| CN (1) | CN1856312A (de) |
| AR (1) | AR045926A1 (de) |
| AT (1) | ATE374030T1 (de) |
| AU (1) | AU2004262897B9 (de) |
| BR (1) | BRPI0412919A (de) |
| CA (1) | CA2532347C (de) |
| CO (1) | CO5640124A2 (de) |
| DE (1) | DE602004009195T2 (de) |
| DK (1) | DK1651234T3 (de) |
| ES (1) | ES2293287T3 (de) |
| HR (1) | HRP20070552T3 (de) |
| IL (1) | IL173131A (de) |
| MX (1) | MXPA06000705A (de) |
| MY (1) | MY138394A (de) |
| NO (1) | NO20060328L (de) |
| NZ (1) | NZ544719A (de) |
| PL (1) | PL1651234T3 (de) |
| PT (1) | PT1651234E (de) |
| RU (1) | RU2357734C2 (de) |
| SI (1) | SI1651234T1 (de) |
| TW (1) | TW200524614A (de) |
| WO (1) | WO2005014002A1 (de) |
| ZA (1) | ZA200600693B (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050222175A1 (en) * | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US7612078B2 (en) * | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US7488736B2 (en) * | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| US7598265B2 (en) * | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
| US7576211B2 (en) * | 2004-09-30 | 2009-08-18 | Epix Delaware, Inc. | Synthesis of thienopyridinone compounds and related intermediates |
| US7407966B2 (en) * | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2258359A3 (de) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| EP2314289A1 (de) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba-rezeptor-vermittelte modulation von neurogenese |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| CA2651862A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| EP2445877B1 (de) * | 2008-12-03 | 2014-07-23 | Nanotherapeutics, Inc. | Bicyclische verbindungen und verfahren zu deren herstellung und deren verwendung |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US8541404B2 (en) * | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| RU2472475C2 (ru) * | 2010-04-20 | 2013-01-20 | Учреждение образования "Белорусский государственный медицинский университет" (УО БГМУ) | Способ комбинированного лечения глаукомной оптической нейропатии |
| KR20150070187A (ko) | 2012-10-23 | 2015-06-24 | 에프. 호프만-라 로슈 아게 | 자폐 장애의 치료를 위한 ｍｇｌｕ２／３ 길항제 |
| KR20160143853A (ko) | 2014-04-23 | 2016-12-14 | 에프. 호프만-라 로슈 아게 | 지적 장애의 치료를 위한 mglu2/3 길항제 |
| CN112462047B (zh) * | 2020-11-13 | 2023-02-07 | 北京元恩生物技术有限公司 | 一种尼卡巴嗪检测试剂盒及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| DK1089976T3 (da) * | 1998-06-22 | 2004-01-19 | Neurosearch As | Fremgangsmåde til fremstilling af 5-bromisoquinolin og dets 8-nitroderivat |
| US6194403B1 (en) * | 1999-09-09 | 2001-02-27 | Unitech Pharmaceuticals, Inc. | Tacrine derivatives for treating Alzheimer's disease |
| ATE261945T1 (de) * | 1999-10-15 | 2004-04-15 | Hoffmann La Roche | Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten |
| ATE250039T1 (de) * | 1999-10-15 | 2003-10-15 | Hoffmann La Roche | Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten |
| CA2310926C (en) * | 2000-04-03 | 2002-10-15 | Janssen Pharmaceutica N.V. | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
| EP1203584A1 (de) | 2000-10-13 | 2002-05-08 | M.D.M. S.r.l. | Cholinerger Vorläufer (insbesondere Cholin-alfoscerat) assoziiert mit einem Acetylcholinesterase Inhibitor (wie z.B. Rivastigmin, Donepezil) |
| US6500972B2 (en) * | 2001-01-03 | 2002-12-31 | Chinese Petroleim Corp. | Synthesis of TMBQ with transition metal-containing molecular sieve as catalysts |
| US6500955B1 (en) * | 2001-02-02 | 2002-12-31 | National Institute Of Pharmaceutical Education And Research | One pot synthesis of [2,8-Bis (trifluoromethyl)-4-quinolinyl]-2-pyridinylmethanone, a mefloquine intermediate |
| CN100390235C (zh) * | 2001-04-09 | 2008-05-28 | 富士胶片株式会社 | 偶氮化合物及其生产方法、中间体化合物和利用该化合物生产偶氮化合物的方法 |
| NZ528345A (en) * | 2001-04-12 | 2005-04-29 | F | Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mGluR2 antagonists I |
| CA2442557C (en) * | 2001-04-12 | 2008-12-23 | F. Hoffmann-La Roche Ag | Dihydro-benzo¬b|¬1,4|diazepin-2-one derivatives as mglur2 antagonists ii |
| US6949542B2 (en) * | 2002-02-06 | 2005-09-27 | Hoffman-La Roche Inc. | Dihydro-benzo[b][1,4]diazepin-2-one derivatives |
-
2004
- 2004-07-17 AT AT04741126T patent/ATE374030T1/de active
- 2004-07-17 KR KR1020067001762A patent/KR100764330B1/ko not_active Expired - Fee Related
- 2004-07-17 PL PL04741126T patent/PL1651234T3/pl unknown
- 2004-07-17 WO PCT/EP2004/008020 patent/WO2005014002A1/en not_active Ceased
- 2004-07-17 CN CNA2004800278083A patent/CN1856312A/zh active Pending
- 2004-07-17 ES ES04741126T patent/ES2293287T3/es not_active Expired - Lifetime
- 2004-07-17 EP EP04741126A patent/EP1651234B1/de not_active Expired - Lifetime
- 2004-07-17 HR HR20070552T patent/HRP20070552T3/xx unknown
- 2004-07-17 DK DK04741126T patent/DK1651234T3/da active
- 2004-07-17 PT PT04741126T patent/PT1651234E/pt unknown
- 2004-07-17 SI SI200430524T patent/SI1651234T1/sl unknown
- 2004-07-17 BR BRPI0412919-9A patent/BRPI0412919A/pt not_active Application Discontinuation
- 2004-07-17 MX MXPA06000705A patent/MXPA06000705A/es active IP Right Grant
- 2004-07-17 AU AU2004262897A patent/AU2004262897B9/en not_active Ceased
- 2004-07-17 CA CA2532347A patent/CA2532347C/en not_active Expired - Fee Related
- 2004-07-17 DE DE602004009195T patent/DE602004009195T2/de not_active Expired - Lifetime
- 2004-07-17 NZ NZ544719A patent/NZ544719A/xx unknown
- 2004-07-17 RU RU2006105721/15A patent/RU2357734C2/ru not_active IP Right Cessation
- 2004-07-17 JP JP2006521458A patent/JP5005343B2/ja not_active Expired - Fee Related
- 2004-07-21 TW TW093121764A patent/TW200524614A/zh unknown
- 2004-07-22 US US10/896,494 patent/US7235547B2/en not_active Expired - Fee Related
- 2004-07-22 AR ARP040102592A patent/AR045926A1/es not_active Application Discontinuation
- 2004-07-23 MY MYPI20042981A patent/MY138394A/en unknown
-
2006
- 2006-01-12 IL IL173131A patent/IL173131A/en not_active IP Right Cessation
- 2006-01-20 NO NO20060328A patent/NO20060328L/no not_active Application Discontinuation
- 2006-01-24 CO CO06006378A patent/CO5640124A2/es not_active Application Discontinuation
- 2006-01-24 ZA ZA200600693A patent/ZA200600693B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE374030T1 (de) | Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten | |
| DE60324777D1 (de) | Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten | |
| EP2073811A4 (de) | Kinasehemmer zur behandlung myleoproliferativer und anderer proliferativer erkrankungen | |
| DE60114580D1 (de) | Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen | |
| ATE513550T1 (de) | Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung | |
| EP1628530A4 (de) | Verfahren und zusammensetzungen zur vorbeugung und behandlung von sepsis | |
| ATE414519T1 (de) | Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit | |
| DE602004020660D1 (de) | Pyrazolylderivative in form von arzneimitteln zur behandlung von akuten oder chronischen neuronalen regressionen | |
| EP2148683A4 (de) | Verfahren zur sicheren und wirksamen behandlung und prävention von sekundärer hyperparathyreose bei chronischer nierenerkrankung | |
| DE60221798D1 (de) | Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen | |
| NO20082894L (no) | Metode for behandling av kognitiv dysfunksjon | |
| DE60134009D1 (de) | Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose | |
| EP1786428A4 (de) | Pde5-hemmer-zusammensetzungen und verfahren zur behandlung von herzerkrankungen | |
| EP1546285A4 (de) | Nitrifikationshemmende behandlung von weideb den | |
| DE602005017373D1 (de) | Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten | |
| EP1905452A4 (de) | Wirkstoff zur prävention oder behandlung von glaukomen | |
| ATE469886T1 (de) | 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen | |
| ATE423099T1 (de) | Zur behandlung von schmerzen geeignete piperazine | |
| DE60224004D1 (de) | Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten | |
| ATE429222T1 (de) | Medikamente zur behandlung oder prävention fibrotischer krankheiten | |
| DE602005010222D1 (de) | Verwendung eines phenothiazin-derivats zur prävention und/oder behandlung von gerhörverlust | |
| DE602004016830D1 (de) | Pharmazeutische zusammensetzungen mit einer kombination aus rapamycin oder seinen derivaten und pimecrolimus zur behandlung von entzündlicher darmerkrankung (ibd) | |
| ATE429221T1 (de) | Medikamente zur behandlung oder prävention fibrotischer krankheiten | |
| DE60331359D1 (de) | Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes | |
| DE602005016141D1 (de) | S-mirtazapin zur behandlung von hitzewallungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1651234 Country of ref document: EP |